About: The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 28 October 2010

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) bài báo khoa học (vi) article scientifique (fr) artículu científicu espublizáu en 2010 (ast) наукова стаття, опублікована в жовтні 2010 (uk) مقالة علمية نشرت في 28 أكتوبر 2010 (ar) scientific article published on 28 October 2010 (en)
publication date	wds:Q37803416-3C62C5CF-9FA9-449B-ADF3-E62B220E2F89
publication date	2010-10-28 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37803416-77E3FFC1-E2A5-400B-A6AB-25A3A615BB4C
language of work or name	English
cites work	wds:Q37803416-093711CD-F7F0-452B-805A-4945880ADB7D wds:Q37803416-0D8F2014-2DF4-4DAA-BBE3-B4CB0BCD1BAA wds:Q37803416-13FEC354-25B8-4961-A131-24C393DA30EB wds:Q37803416-190766E1-F396-42E2-9C63-DD4EB950F522 wds:Q37803416-261FCEC7-B5E8-48AB-BAE2-1813018C7FC0 wds:Q37803416-2D2787B6-1851-4F7E-BB14-026D995E275F wds:Q37803416-2DAD1E0A-2B4A-4B5F-A51A-22AEE495339D wds:Q37803416-32291037-F6E0-4718-BAE4-B79252D0AED3 wds:Q37803416-41E2D4C6-0018-429A-9D01-5B9467E2B0E1 wds:Q37803416-475090A8-CC11-4D5F-8E9A-827AAAEAD657 wds:Q37803416-488DB354-8CA3-465C-8C5C-8B0DF139C480 wds:Q37803416-4A379F63-E8C6-43D7-A6D0-9EF686736559 wds:Q37803416-563AA3AC-8A23-4852-AB3E-12E1392BDB21 wds:Q37803416-572DD8A8-46CF-4521-99F3-597B8DBC8F20 wds:Q37803416-57961A11-6738-4F7E-ABDB-FD8BCE4782E0 wds:Q37803416-601E39EA-DD17-498F-966A-1BB96C3359C2 wds:Q37803416-63534B75-3D8C-41B5-A653-75B5B5782153 wds:Q37803416-66E85C5F-DC44-45DC-9789-571798921118 wds:Q37803416-6E059F32-9F26-44B3-B775-7A952F4E6549 wds:Q37803416-71E5EE18-2C6B-4640-86D3-E53768D94487 wds:Q37803416-74B268D6-E54E-4992-84B8-A49ED085603C wds:Q37803416-955B19A0-5707-4711-8878-76C7BD9360B9 wds:Q37803416-9B9E7355-EFFA-4193-AD7D-B9938C751902 wds:Q37803416-9BE21370-B36F-446D-8818-8BD4008376B1 wds:Q37803416-9C8B1D25-2610-4E02-B805-21CF2E79C871 wds:Q37803416-9F5C7B3A-8101-40FA-9123-33CEC3C69AA1 wds:Q37803416-A643D83D-3399-4835-8561-013E1AC5C7C6 wds:Q37803416-AEE3126E-3D91-4558-9A9C-AEF0DDD1DCEA wds:Q37803416-BCB9BD04-14C0-4D8E-96EB-52335C705774 wds:Q37803416-C81AA3B8-C620-4A61-B764-F59E11903675 wds:Q37803416-CEE9BECA-13D7-4FF7-B841-15E7FEC26914 wds:Q37803416-D6468239-D55B-4155-AC1C-74759ED88E72 wds:Q37803416-E5070213-A35A-4173-9639-259FBF5D7CFE
cites work	Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? The German etanercept registry for treatment of juvenile idiopathic arthritis Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis Anakinra for systemic juvenile arthritis: the Rocky Mountain experience Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children Unlicensed and off label drug use by children in the community: cross sectional study Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA? The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry Defining off-label and unlicensed use of medicines for children: results of a Delphi survey Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret®) in systemic juvenile idiopathic arthritis The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis Adult outcomes of patients with juvenile idiopathic arthritis Pharmacokinetics of anakinra in subjects with different levels of renal function A case of macrophage activation syndrome successfully treated with anakinra Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Burden and cost of illness in patients with juvenile idiopathic arthritis Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist Early effects of Anakinra in corticosteroid naïve SOJIA patients Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF. Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, double-blind, placebo-controlled trial (ANAJIS).
author name string	wds:Q37803416-6F8ABBA8-ED82-4F6A-A61A-66C7B2616756 wds:Q37803416-77A797CB-DCBB-479F-830B-021BC723B292 wds:Q37803416-EDD43DAC-5647-40E6-8AB6-31B8991CAADA
author name string	Daantje Barug Joost Frans Swart Michelle Möhlmann
rdfs:label	The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis (en) The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis (nl) The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis (ast)
skos:prefLabel	The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis (en) The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis (nl) The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis (ast)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software